Asda is to sell cancer drugs at cost price in an attempt to reduce the cost of cancer drugs. The supermarket chain, owned by Wal-Mart, is attempting a similar scheme for IVF treatments. Asda has called on pharmacists to lower the cost of the expensive medications. Patients who have cancer will find the scheme a huge help and will save thousands of pounds. Many of the treatments available on the NHS are so expensive that they are not always affordable for patients.
There is a large market for cancer drugs in China, driven by the high incidence rate and growing healthcare expenditure. The disease is increasing in prevalence due to increasing age, as the population ages and lifestyles change. Other risk factors that increase cancer risk include tobacco use, physical inactivity, excess boy weight, and reproductive patterns. By 2021, the world’s cancer numbers are expected to reach 10 million cases and 15 million deaths, making the market for cancer drugs highly profitable. Продать онкопрепараты
In the U.S., the top 15 cancer drugs are expected to bring in almost $90 billion in sales. That’s nearly double the market for all cancer drugs. This is more than four times what pharma made in China and Japan combined in 2014. And the growth of cancer drug sales is projected to continue for the next three years. But how do pharmaceutical companies make their money? They sell more drugs than ever. The most profitable companies know how to increase their profits by selling more of these medications.
One example of a pharmaceutical company with a high cancer drug market share is Aurobindo Pharma Limited. The Hyderabad-based pharmaceutical company plans to receive approvals for three to four oncology products by March 2018 and expects to make $90 billion over the next 10 years. The company hopes to achieve these goals despite the fact that it is a high-margin product business. The cancer drugs it sells in China are also highly profitable, and the high-margin market represents a significant part of its total revenue.
Aurobindo Pharma Limited aims to receive three-four oncology drug approvals by March 2018. The company is in the high-margin product business, and has recently announced its first clinical trial for Agene Peptidex. In addition, the company has seen rapid growth in its sales and revenues in the past few years, and is now one of the most promising oncology companies in the U.S.
In the US, the cancer drug market is booming. The top 15 cancer drugs will account for one-fourth of pharma’s total revenue in 2022, and will make nearly $90 billion in the next three years. This growth is due to the growing number of new cancer patients and the rapidly developing economy. The pharmaceutical industry is making money in the cancer drug market, and this trend will continue. It is not a good time to sell your cancer medicines, but it is a good time to start.
Patterns Design 
You must be logged in to post a comment.